RxDoctor Payments Data

Andrea Madiedo, MD

Colon & Rectal Surgery · Miami, FLNPI 1811359508

Payments from drug & device makers

What this record shows

This record is dominated by education: $33,500 of the $38,030 with a category attached, or 88.1%. Intuitive Surgical accounts for 95.6% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2023 at $18,073 and has fallen 68.0% since, to $5,785 in 2025.

$38,030in general payments, 2019–2025

Across 57 payments — averaging $667.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$36K
  • Axonics, Inc.$350
  • Guard Medical Inc.$222
  • Boston Scientific$186
  • W. L. Gore & Associates, Inc.$184
  • Braintree Laboratories, Inc.$157
  • plus $573 from 9 others

What the payments were for

  • Travel & lodging$2,5117%
  • Food & beverage$2,0195%
  • Education$33,50088%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$38,030 in reported general payments places this provider in the 80th percentile of 157 colon & rectal surgery providers in Florida.

See all colon & rectal surgery providers in Florida

Medicare billing

Part B allowed, 2024
$47,462
Medicare patients
122
Services billed
252

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SutabSod Sulf/Pot Chloride/Mag Sulf52$8,587
LinzessLinaclotide11$5,650
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates52$3,293
Neomycin Sulfate36$203
Ibuprofen53$179
Hydrocortisone12$75
Tramadol Hcl43$69
Metronidazole37$53
Gabapentin15$46
Tamsulosin Hcl32$18

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Braintree Laboratories, Inc.Sutab$157$8,58752 claims
AbbVieLinzess$13$5,65011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 157 colon & rectal surgery providers in Florida.

Other colon & rectal surgery in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →